Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Pulmonary Hypertension Is A Frequent Event In Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors, Sameh Gaballa, Aref Al-Kali, Hagop Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Mohamad Ayoubi, Gautam Borthakur, S. M. O'Brien, J. E. Cortes
Pulmonary Hypertension Is A Frequent Event In Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors, Sameh Gaballa, Aref Al-Kali, Hagop Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Mohamad Ayoubi, Gautam Borthakur, S. M. O'Brien, J. E. Cortes
Division of Internal Medicine Faculty Papers & Presentations
Poster presented at American Society of Clinical Oncology in Chicago Illinois.
Background: Tyrosine kinase inhibitors (TKI) are the current standard therapy for patients with chronic myeloid leukemia (CML). Fluid retention and pleural effusions have been reported in patients treated with TKIs, particularly with dasatinib. Although TKIs have been shown to reverse pulmonary hypertension (PH) in animal models, there have been some reports of development of reversible PH with dasatinib.
Methods: We conducted a retrospective analysis on 401 patients diagnosed with CML in chronic phase (CP) who were treated with TKIs (imatinib, dasatinib, or nilotinib) as initial therapy for CML and …